Literature DB >> 6358654

Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation.

G Thiel, F Harder, R Lörtscher, M Brünisholz, J Landmann, F Brunner, F Follath, M Wenk, M Mihatsch.   

Abstract

The actual survival rate of 25 primary cadaveric kidney grafts in recipients treated initially with cyclosporin A (CyA) alone was 84%. The survival rate in 37 patients under conventional immunosuppression was 76%. The mean number of dialyses required in the first 4 weeks after transplantation was 1.2 per patient in both groups. At 15-28 months posttransplant, mean serum creatinine levels have remained stable at 175 mumol/l in the CyA group. The mean daily dose of steroids (including methylprednisolone i.v.) in the first two months was 2.07 mg/kg/d in patients under conventional immunosuppression and 0.76 mg/kg/d in the patients receiving CyA (p less than 0.001). The combination of CyA with low-dose steroids enabled the dose of CyA to be rapidly tapered off in once-weekly steps. CyA levels were monitored by determination of whole blood trough concentrations (target level: 300-800 ng/ml). At 60 days posttransplant the average dose of CyA was 6.0 +/- 0.5 mg/kg/d compared with an average daily dose of 11.4 +/- 0.9 as recommended for CyA alone in the protocol for the European multicentre study. This more rapid reduction in the CyA dose reduced nephrotoxicity (serum creatinine levels 174 +/- 14 as compared with 289 +/- 31 mumol/l) (p less than 0.05) and almost halved the number of methylprednisolone pulses given up to the end of the second month. We conclude from these results (1) that previously the dosage of CyA administered at this centre was probably too high, and (2) early adjustment of dose levels on the basis of blood concentrations and with low-dose prednisone cover appears to be safe and effective, but requires further verification.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6358654     DOI: 10.1007/bf01537497

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  Giant mitochondria in renal tubular cells and cyclosporin A.

Authors:  M J Mihatsch; W Olivieri; U Marbet; G Thiel; F Harder; H U Zollinger
Journal:  Lancet       Date:  1981-05-23       Impact factor: 79.321

2.  Hyperbilirubinaemia and cyclosporin A levels in renal transplant patients.

Authors:  R Loertscher; M Wenk; F Harder; F Brunner; F Follath; G Thiel
Journal:  Lancet       Date:  1981-09-19       Impact factor: 79.321

3.  Persistent elevation of alkaline phosphatase in cyclosporine-treated renal transplant recipients.

Authors:  R Loertscher; G Thiel; F Harder; F P Brunner
Journal:  Transplantation       Date:  1983-07       Impact factor: 4.939

4.  [Basic immunosuppressive therapy following kidney transplantation. Cyclosporin A in combination with small doses of methylprednisolone, without regard to selection criteria. Preliminary report].

Authors:  W Land; L A Castro; G Hillebrand; W D Illner; B Schneider; W Siebert; R Zink; E Albert
Journal:  Fortschr Med       Date:  1982-11-04

5.  Renal toxicity of cyclosporin A in the rat.

Authors:  G Thiel; J Torhorst; F P Brunner
Journal:  Proc Clin Dial Transplant Forum       Date:  1980

6.  [Renal side effects of treatment with cyclosporin A in rheumatoid arthritis and after bone marrow transplantation].

Authors:  U A Marbet; U Graf; M J Mihatsch; A Gratwohl; W Müller; G Thiel
Journal:  Schweiz Med Wochenschr       Date:  1980-12-27

7.  Cyclosporin A hepatotoxicity in 66 renal allograft recipients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

8.  Immunological and pharmacological monitoring in the clinical use of cyclosporin A.

Authors:  P A Keown; C R Stiller; R A Ulan; N R Sinclair; W J Wall; G Carruthers; W Howson
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

9.  Cyclosporin A in renal transplantation: a prospective randomized trial.

Authors:  R M Ferguson; J J Rynasiewicz; D E Sutherland; R L Simmons; J S Najarian
Journal:  Surgery       Date:  1982-08       Impact factor: 3.982

10.  Intravenous cyclosporine kinetics in renal failure.

Authors:  F Follath; M Wenk; S Vozeh; G Thiel; F Brunner; R Loertscher; M Lemaire; K Nussbaumer; W Niederberger; A Wood
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

View more
  7 in total

1.  Experience with cyclosporine and steroids in clinical renal transplantation.

Authors:  N L Tilney; E L Milford; J L Araujo; T B Strom; C B Carpenter; R L Kirkman
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

2.  Antazoline as an adjuvant in immunosuppressive therapy in renal transplant patients.

Authors:  A Montandon; D Brügger; J Hodler
Journal:  Klin Wochenschr       Date:  1986-06-16

3.  Morphological differentiation between rejection and cyclosporin nephrotoxicity in renal allografts.

Authors:  G H Neild; D H Taube; R B Hartley; L Bignardi; J S Cameron; D G Williams; C S Ogg; C J Rudge
Journal:  J Clin Pathol       Date:  1986-02       Impact factor: 3.411

4.  Arteriolosclerosis of the human renal allograft: morphology, origin, life history and relationship to cyclosporine therapy.

Authors:  P Rossmann; J Jirka; M Chadimová; I Reneltová; F Saudek
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Acute rejection episodes after renal transplantation in children under cyclosporin A treatment.

Authors:  P F Hoyer; G Offner; H P Krohn; J Brodehl
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

6.  Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation.

Authors:  Anouk A J Hamers; Sunil K Joshi; Asha B Pillai
Journal:  OBM Transplant       Date:  2019-01-31

Review 7.  Transplant tolerance: new insights and strategies for long-term allograft acceptance.

Authors:  Paulina Ruiz; Paula Maldonado; Yessia Hidalgo; Alejandra Gleisner; Daniela Sauma; Cinthia Silva; Juan Jose Saez; Sarah Nuñez; Mario Rosemblatt; Maria Rosa Bono
Journal:  Clin Dev Immunol       Date:  2013-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.